Top

Published in:

01-07-2013 | Original Article

Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities

Authors: Cristian Palmiere, Michele Mussap, Daniel Bardy, Francesco Cibecchini, Patrice Mangin

Published in: International Journal of Legal Medicine | Issue 4/2013

Abstract

The first aim of this study was to assess the diagnostic performance of presepsin (sCD14-ST) in postmortem serum from femoral blood compared to procalcitonin (PCT) to detect sepsis-related fatalities. The second aim was to compare sCD14-ST levels found in postmortem serum to the values in pericardial fluid to investigate the usefulness of the latter as an alternative biological fluid. Two study groups were formed, a sepsis-related fatalities group and a control group. Radiology (unenhanced CT scans and postmortem angiographies), autopsies, histology, neuropathology, and toxicology as well as other postmortem biochemistry investigations were performed in all cases. Microbiological investigations on right cardiac blood were carried out exclusively in septic cases. The results of this study indicated that postmortem serum PCT and sCD14-ST levels, individually considered, allowed septic cases to be identified. Even though increases in both PCT and sCD14-ST concentrations were observed in the control cases, coherent PCT and sCD14-ST results in cases with suspected sepsis allowed the diagnosis to be confirmed. Conversely, no relevant correlation was identified between postmortem serum and pericardial fluid sCD14-ST levels in either the septic or control groups.

Gaïni A, Koldkjaer OG, Møller HJ, Pedersen C, Pedersen SS (2007) Comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: A prospective study. Crit Care 11(4):R76. doi:10.1186/cc5967 PubMedCrossRef

Schrag B, Iglesias K, Mangin P, Palmiere C (2012) Procalcitonin and C-reactive protein in pericardial fluid for postmortem diagnosis of sepsis. Int J Leg Med 126(4):567–72CrossRef

Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A, Esquerda A (2009) Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 34(6):1383–9PubMedCrossRef

Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y (2012) Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. doi:10.1007/s10156-012-0435-2

Palmiere C, Mangin P (2012) Postmortem chemistry update part II. Int J Leg Med 126(2):199–215CrossRef

Schrag B, Roux-Lombard P, Schneiter D, Vaucher P, Mangin P, Palmiere C (2012) Evaluation of C-reactive protein, procalcitonin, tumor necrosis factor alpha, interleukin-6, and interleukin-8 as diagnostic parameters in sepsis-related fatalities. Int J Legal Med 126(4):505–12PubMedCrossRef

Herrmann W, Ecker D, Quast S, Klieden M, Rose S, Marzi I (2000) Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 38(1):41–6PubMedCrossRef

Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40(7):1250–6PubMed

Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L (2000) Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 343(16):1139–47PubMedCrossRef

10.

Reinhart K, Meisner M, Brinkhorst FM (2006) Markers for sepsis diagnosis: What is useful? Crit Care Clin 22(6):503–19PubMedCrossRef

11.

Tong HS, Liu YS, Wen Q, Tang YQ, Yuan FF, Su L (2012) Serum procalcitonin predicting mortality in exertional heatstroke. Emerg Med J 29(2):113–7PubMedCrossRef

12.

Hausfater P, Hurtado M, Pease S, Juillien G, Lvovschi VE, Salehabadi S, Lidove O, Wollf M, Bernard M, Chollet-Martin S, Riou B (2008) Is procalcitonine a marker of critical illness in heatstroke? Intensive Care Med 34(8):1377–83PubMedCrossRef

13.

Nylén ES, Al Arifi A, Becker KL, Snider RH Jr, Alzeer A (1997) Effect of classic heatstroke on serum procalcitonin. Crit Care Med 25(8):1362–5PubMedCrossRef

14.

Balci C, Sivaci R, Akbulut G, Karabekir HS (2009) Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res 37(6):1709–17PubMedCrossRef

15.

Maier M, Wutzler S, Lehnert M, Szermutzky M, Wyen H, Bingold T, Henrich D, Walcher F, Marzi I (2009) Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma 66(1):243–9PubMedCrossRef

16.

Mussap M, Degrandi R, Cataldi L, Fanos V, Plebani M (2007) Biochemical markers for the early assessment of neonatal sepsis: The role of procalcitonin. J Chemother 19(Suppl 2):35–8PubMed

17.

Mussap M, Noto A, Fravega M, Fanos V (2011) Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: New clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 24(Suppl 2):12–4PubMedCrossRef

18.

Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C (2004) CD14 is an acute-phase protein. J Immunol 172(7):4470–9PubMed

19.

Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, Miyata M, Furusako S, Endo S (2005) Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 11(5):234–8PubMedCrossRef

20.

Obata K, Segawa O, Yakabe M, Ishida Y, Kuroita T, Ikeda K, Kawakami B, Kawamura Y, Yohda M, Matsunaga T, Tajima H (2001) Development of a novel method for operating magnetic particles, Magtration Technology, and its use for automating nucleic acid purification. J Biosci Bioeng 91(5):500–3PubMed

21.

Okamura Y, Yokoi H (2011) Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 412(23–24):2157–61PubMedCrossRef

22.

NCCLS. Protocols for determination of limits of detection and limits of quantitation; approved guideline. NCCLS document 2004 EP17-A [ISBN 1-56238-551-8]. Nccls, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898 USA, 2004.

23.

Pavnik-Arnol M, Hojker S, Derganc M (2007) Lypopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 33(6):1025–32CrossRef

24.

Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M (2011) Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection 39(5):411–7PubMedCrossRef

25.

Tsokos M (2007) Postmortem diagnosis of sepsis. Forensic Sci Int 165(2–3):155–64PubMedCrossRef

26.

Tsokos M, Reichelt U, Nierhaus A, Püschel K (2001) Serum procalcitonin (PCT): A valuable biochemical parameter for the postmortem diagnosis of sepsis. Int J Legal Med 114(4–5):237–43PubMedCrossRef

27.

Tsokos M, Reichelt U, Jung R, Nierhaus A, Püschel K (2001) Interleukin-6 and C-reactive protein serum levels in sepsis-related fatalities during the early postmortem period. Forensic Sci Int 119(1):47–56PubMedCrossRef

28.

Tsokos M, Fehlauer F, Püschel K (2000) Immunohistochemical expression of E-selectin in sepsis-induced lung injury. Int J Legal Med 113(6):338–42PubMedCrossRef

29.

Tsokos M, Fehlauer F (2001) Postmortem markers of sepsis: An immunohistochemical study using VLA-4 (CD49d/CD29) and ICAM-1 (CD54) for the detection of sepsis-induced lung injury. Int J Legal Med 114:291–94PubMedCrossRef

30.

Reichelt U, Jung R, Nierhaus A, Tsokos M (2005) Serial monitoring of interleukin-1β, soluble interleukin-2 receptor and lipopolysaccharide binding protein levels after death. A comparative evaluation of potential postmortem markers of sepsis. Int J Legal Med 119(2):80–87PubMedCrossRef

31.

Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249(4975):1431–3PubMedCrossRef

32.

Krüger C, Schütt C, Obertacke U, Joka T, Müller FE, Knöller J, Köller M, König W, Schönfeld W (1991) Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol 85(2):297–301PubMedCrossRef

33.

Jabara HH, Vercelli D (1994) Engagement of CD14 on monocytes inhibits the synthesis of human Igs, including IgE. J Immunol 153(3):972–8PubMed

34.

Bussolati B, David S, Cambi V, Tobias PS, Camussi G (2002) Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med 10(4):441–9PubMed

35.

Berner R, Fürll B, Stelter F, Dröse J, Müller HP, Schütt C (2002) Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol 9(2):440–5PubMed

36.

Aalto H, Takala A, Kautiainen H, Siitonen S, Repo H (2007) Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection. Scand J Infect Dis 39(6–7):596–603PubMedCrossRef

37.

Takeshita S, Nakatani K, Tsujimoto H, Kawamura Y, Kawase H, Sekine I (2000) Increased levels of circulating soluble CD14 in Kawasaki disease. Clin Exp Immunol 119(2):376–81PubMedCrossRef

38.

Wüthrich B, Kägi MK, Joller-Jemelka H (1992) Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Arch Dermatol Res 284(6):339–42PubMedCrossRef

39.

Oesterreicher C, Pfeffel F, Petermann D, Müller C (1995) Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol 23(4):396–402PubMedCrossRef

40.

Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91(2):207–13PubMedCrossRef

41.

Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, Nakamura T, Tsukano M, Matsuyama T (1998) Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: In the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 17(6):237–43PubMedCrossRef

42.

Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dörner T (2000) Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 9(8):614–21PubMedCrossRef

43.

Nockher WA, Wigand R, Schoeppe W, Scherberich JE (1994) Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 96(1):15–9PubMedCrossRef

44.

Gebhard F, Rösch M, Helm M, Strecker W, Buttenschön K, Kinzl L, Bock KH, Brückner UB (1997) Is the activity of soluble CD14 enhanced following major trauma? Arch Surg 132(10):1116–20PubMedCrossRef

45.

Carrillo EH, Gordon L, Goode E, Davis E, Polk HC Jr (2001) Early elevation of soluble CD14 may help identify trauma patients at high risk for infection. J Trauma 50(5):810–6PubMedCrossRef

46.

Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T (1995) Increased circulating soluble CD14 is associated with high mortality in gram-negative septic shock. J Infect Dis 171(3):639–44PubMedCrossRef

47.

Landmann R, Reber AM, Sansano S, Zimmerli W (1996) Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 173(3):661–8PubMedCrossRef

48.

Blanco A, Solis G, Arranz E, Coto GD, Ramos A, Telleria J (1996) Serum levels of CD14 in neonatal sepsis by Gram-positive and Gram-negative bacteria. Acta Paediatr 85(6):728–32PubMedCrossRef

49.

Kitchens RL, Thompson PA (2003) Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: Roles of soluble CD14, LBP, and acute phase lipoproteins. J Endotoxin Res 9(2):113–8PubMed

50.

Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S (2011) Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 17(6):764–9PubMedCrossRef

51.

Maeda H, Zhu BL, Bessho Y, Ishikawa T, Quan L, Michiue T, Zhao D, Li DR, Komatsu A (2008) Postmortem serum nitrogen compounds and C-reactive protein levels with special regard to investigation of fatal hyperthermia. Forensic Sci Med Pathol 4(3):175–80PubMedCrossRef

Title: Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities
Authors: Cristian Palmiere
Michele Mussap
Daniel Bardy
Francesco Cibecchini
Patrice Mangin
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: International Journal of Legal Medicine / Issue 4/2013
Print ISSN: 0937-9827
Electronic ISSN: 1437-1596
DOI: https://doi.org/10.1007/s00414-012-0804-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

An evaluation of luminol formulations and their effect on DNA profiling

Development and validation of a multiplex reaction analyzing eight miniSTRs of the X chromosome for identity and kinship testing with degraded DNA

Determination of latent fingerprint degradation patterns—a real fieldwork study

Muzzle-loading weapons discharging spherical lead bullets: two case studies and experimental simulation using a skin–soap composite model

Ballistic parameters and trauma potential of pistol crossbows

Mitochondrial DNA control region variation from samples of the Moroccan population